

Figure 2. Intrarectally administrated splenic CD4$^+$ T cells can penetrate gut epithelial monolayers and expand not only in colonic lamina propria but also outside the intestine. (*A*) C.B-17 SCID recipient mice were administered with splenic CD4$^+$ T cells from normal BALB/c mice intrarectally (5 × 10^6, *IR-SCID mice*, n = 9) or intraperitoneally (5 × 10^5, *IP-SCID mice*, n = 9). (*B*) LP, MLN, and SP CD3$^+$CD4$^+$ T cells were isolated from the colon at 10 weeks after T-cell administration, and the number of CD3$^+$CD4$^+$ cells was determined by flow cytometry. Data are indicated as the mean ± standard error (SEM) of mean of 9 mice in each group. *$P < .01$. (*C*) RAG-2$^{-/-}$ mice were pretreated just like protocol of Supplementary Figure 1 (Mice with Niflec/Pronase) or without the pretreatments of Niflec and pronase (*Mice w/o Niflec/Pronase*) before cell administration. RAG-2$^{-/-}$ mice in each group were administered with 5 × 10^6 CD4$^+$ T cells from EGFP-Tg mice (n = 10 in each group). (*D*) LP, MLN, and SP GFP$^+$CD4$^+$ cells were isolated from the colon at 24 hours after cell administration, and the absolute number of GFP$^+$CD4$^+$ cells was determined by FACS. *Dot plot* analysis data of FACS is representative one of each group. Representatives of 10 separate samples in each group. (*E*) The absolute number of LP GFP$^+$CD4$^+$ cells. Data are indicated as the mean ± SEM of 9 mice in each group. *$P = .034$.

etrating CD4$^+$ T cells in a mechanism of lymphopenia-driven rapid proliferation in a long-term observation.[16] As a protocol of intestinal preparation, mice were maintained without feeding for 3 hours before cell administration and were given 1 mL of Niflec water (Ajinomoto Pharma Co, Tokyo, Japan) 3 times at intervals of 1 hour by oral catheter to remove the resident stool. Mice were then pretreated with or without 50% ethanol enema and thereafter with 5% pronase enema at 1 hour before cell administration (Supplementary Figure 1).

Consistent with previous reports,[17] SCID mice intraperitoneally administered with splenic CD4$^+$ T cells (hereafter called IP-SCID mice) were healthy throughout the observation period and showed no clinical symptoms of colitis as estimated by clinical score, possibly because of the presence of regulatory T (T_R) cells in the donor CD4$^+$ T-cell preparation (Supplementary Figure 2*A* and *B*). Surprisingly, SCID mice intrarectally administered with CD4$^+$ T cells (IR-SCID mice) developed severe colitis with diarrhea, anorectal prolapses, hunched posture, and weight loss in spite of the presence of T_R cells in the donor CD4$^+$ T cells (data not shown). Ten weeks after cell administration, the colon from IR-SCID mice, but not from IP-SCID mice, was enlarged and had a greatly thickened wall (Supplementary Figure 2*A*). The difference in clinical scores at 10 weeks after administration between the 2 groups was significant (Supplementary Figure 2*B*). Histologic examination showed prominent epithelial hyperplasia and loss of goblet cells with massive infiltration of mononuclear cells in the LP of colon from IR-SCID mice but not from IP-SCID mice (Supplementary Figure 2*C*). The difference in histologic scores between the 2 groups was also significant (Supplementary Figure 2*D*).

A further evaluation of CD4$^+$ T-cell infiltration was made by assessing the absolute number of LP CD3$^+$CD4$^+$ T cells. No CD3$^+$CD4$^+$ T cells were recovered from the colonic tissue of SCID mice without cell administration (data not shown). The absolute number of colonic LP CD4$^+$ T cells recovered from IR-SCID mice, but not from IP-SCID mice, far exceeded the number of originally injected cells (Figure 2*B*), indicating penetration of CD4$^+$ T cells from the lumen side to the LP and extensive expansion in the colon in IR-SCID mice during 10 weeks after administration. Furthermore, it was of note that substantial numbers of CD3$^+$CD4$^+$ T cells were also recovered from mesenteric lymph node (MLN), peripheral blood (PB), and spleen (SP) of IR-SCID mice (Figure 2*B*), suggesting that some of the LP CD3$^+$CD4$^+$ T cells in the colon of IR-SCID mice could not only penetrate the LP but also egress from LP to systemic circulation. Flow cytometric analysis revealed that CD3$^+$CD4$^+$ T cells recovered from the LP of IR-SCID or IP-SCID mice are mostly of CD44$^+$CD62L$^-$ effector-memory T (T_{EM}) phenotype irrespective of the presence or absence of colitis (Supplementary Figure 2*E*). To physiologically adopt this cell transfer system in vivo, we also performed it without ethanol preadministration and recovered a small but substantial number of CD3$^+$CD4$^+$ T cells from the LP,

MLN, PB, SP, and bone marrow (BM) of IR-SCID mice 10 weeks after administration (Supplementary Figure 3). We also developed simpler, but surprisingly, more efficient intrarectal cell transfer protocol without the pretreatments of Niflec and pronase as demonstrated in Figure 2*C–E*.

The evidence that intrarectal, but not intraperitoneal, administration of splenic $CD4^+$ T cells induced colitis was surprising (Figure 2), although this donor population contains a substantial number of T_R cells (approximately 10% in total $CD4^+$ T cells, data not shown). To assess this issue, we next administered the same number of whole splenic $CD4^+$ T cells or T_R cell-depleted $CD4^+CD25^-$ T cells into SCID mice (Supplementary Figure 4*A*). As expected, the 2 groups of mice similarly developed colitis (data not shown) and had comparable absolute numbers of $CD3^+CD4^+$ T cells in the LP, MLN, PB, SP, and BM at 7 weeks after cell administration (Supplementary Figure 4*B*), suggesting 3 possibilities: (1) naïve $CD4^+$ T, but not T_R cells, penetrate epithelial barriers; (2) both T_R cells and naïve $CD4^+$ T cells penetrate epithelial barriers, but T_R cells cannot suppress the expansion of naïve $CD4^+$ T cells to become colitogenic $CD4^+$ T cells in the LP; and (3) both T_R cells and naïve $CD4^+$ T cells penetrate epithelial barriers, but naïve $CD4^+$ T cells alone egress the LP and are instructed in MLN to become gut-homing receptor-expressing colitogenic $CD4^+$ T cells (see the following section).

We also investigated whether other lymphocytes can penetrate intestinal epithelial monolayer and egress from LP or not. For this purpose, 1×10^8 splenocytes from $Ly5.1^+$ C57BL/6 mice were intrarectally administered to $Ly5.2^+$ RAG-$2^{-/-}$ recipients ($Ly5.1^+$ IR), and 1×10^7 splenocytes from C57BL/6 mice were intravenously administered to RAG-2 recipients ($Ly5.1^+$ IV). Splenocytes were recovered from mice in each group at 4 weeks after cell administration, and the number of $Ly5.1^+CD3^+CD4^+$ ($CD4^+$ T), $Ly5.1^+CD3^+CD8^+$ ($CD8^+$ T), $Ly5.1^+CD3^+NK1.1^+$ (NKT), $Ly5.1^+CD3^-NK1.1^+$ (NK), $B220^+$ (B) cells were determined by fluorescence-activated cell sorter (Supplementary Figure 5*A*). We confirmed that other lymphocytes such as $CD8^+$ T, B, NK, and NKT cells were also detected in the SP of transferred mice, although the numbers of these cells are lower than that of $CD4^+$ T cells (Supplementary Figure 5*B*).

SCID Mice Intrarectally Transferred With Colitogenic $CD4^+$ T_{EM} Cells Developed Severe Colitis

To characterize further the penetration between epithelial barriers and egress from the LP of $CD4^+$ T cells without the impact of the initiation phase of naïve $CD4^+$ T cells, we next intrarectally administered the same number of colitogenic $CD4^+$ T cells obtained from colitic mice previously transferred with $CD4^+CD45RB^{high}$ T cells or splenic $CD4^+$ T cells from normal mice into SCID mice (Figure 3*A*). Both groups developed colitis as evidenced by clinical and histologic scores, and the recovered number of LP $CD4^+$ T cells (Figure 3*B–D*), suggesting that colitogenic memory $CD4^+$ T cells also can penetrate from the intestinal lumen to the LP following intrarectal administration. However, it was of note that the numbers of $CD4^+$ T cells recovered from MLN, PB, and BM of mice intrarectally administered with colitogenic $CD4^+$ T cells were significantly lower than those of mice administered with splenic $CD4^+$ T cells (Figure 3*D*), suggesting that the former cells have a tendency to remain in the LP and not easily egress to afferent lymphatics. Regarding the role of $CD4^+CD25^+Foxp3^+$ T_R cells in their penetration between epithelial barriers and egress from the LP, it was notable that approximately normal proportion of $CD4^+Foxp3^+$ T_R cells resided in the LP and SP of mice administered with splenic $CD4^+$ T cells, but not with colitogenic $CD4^+$ T cells (Figure 3*E*), suggesting that intrarectally administered T_R cells not only penetrate epithelial barriers but also egress the LP.

Short Time Course Analysis of Intrarectrally Administered $CD4^+$ T Cells

To clarify that intrarectally administered $CD4^+$ T cells continue to reside in the intraepithelial space or LP of mice without the impact of cell proliferation in the lymphopenic condition, we next administered splenic $CD4^+$ T cells into RAG-$2^{-/-}$ mice (hereafter referred to as IR-RAG mice) and visualized the localization of $CD4^+$ T cells by immunohistochemistry at the early time points, 3, 12, and 24 hours after administration. As shown in Figure 4*A*, (1) $CD4^+$ T cells (red) adhering to epithelial cells (green) from the lumen side were detected at 3 hours after administration; (2) many $CD4^+$ T cells were found to reside in the intraepithelial space, and a few $CD4^+$ T cells were detected in the LP at 12 hours after administration; and (3), thereafter, $CD4^+$ T cells were as abundant in the LP as in the epithelial space at 24 hours after administration. To determine further whether $CD4^+$ T cells could penetrate to intestinal barriers from the lumen side, we next conducted an electron microscopic analysis using intestinal samples at 6 hours after administration. As expected, we found that small lymphocytes with round nuclei and smooth surfaces resided in the intraepithelial space with normal epithelial structure in IR-RAG mice (Figure 4*B*).

To rule out the possibility that intrarectally administered cells might have directly entered the small blood vessels that were exposed to the damaged intestinal lumen by the ethanol treatment, we next checked the time course of the first emergence of $CD4^+$ T cells from the LP, MLN, and SP. To this end, splenic $CD4^+$ T cells from CAG-GFP Tg mice were administered intravenously or intrarectally to RAG-$2^{-/-}$ mice to precisely determine the absolute number of $CD4^+$ T cells. In RAG-$2^{-/-}$ mice intravenously administered with $CD4^+$ T cells (GFP-IV mice), GFP^+ cells were detected in MLN and SP, but not the LP, at 6 hours or 24 hours after administration and in the LP as well as MLN and SP at 168 hours after administration (Figure 5). In contrast, in RAG-$2^{-/-}$ mice intrarectally administered with $CD4^+$ T cells (GFP-IR mice), GFP^+ cells were found only in the LP or MLN, but not in the SP, at 6 hours after admin-

BASIC AND TRANSLATIONAL AT



Figure 3. Intrarectally administered colitogenic memory CD4$^+$ T cells not only penetrate intestinal epithelial barriers and reside in the LP but also migrate to MLN and SP. (*A*) SCID recipient mice were intrarectally administered CD4$^+$ T cells from normal BALB/c mice (5 × 10^6, *Normal SP-IR mice*, n = 7) or CD4$^+$ T cells from colitic SCID mice previously transferred with CD4$^+$CD45RB^{high} T cells (5 × 10^6, *Colitic LP-IR mice*, n = 7). (*B-a*) Gross appearance of the colon from *Normal SP-IR* mice and *Colitic LP-IR* mice at 10 weeks after cell administration. (*B-b*) Clinical scores were determined at 10 weeks after administration as described in the Materials and Methods section. Data are indicated as the mean ± standard error of mean (SEM) of 7 mice in each group. *$P < .01$. (*C-a*) Histologic examination of the colon at 10 weeks after administration. Original magnification, ×40 (*upper panels*) and ×100 (*lower panels*). (*C-b*) Histologic scores were determined at 10 weeks after transfer as described in the Materials and Methods section. Data are indicated as mean ± SEM of 7 mice in each group. *$P < .05$. (*D*) LP, MLN, and spleen CD3$^+$CD4$^+$ T cells were isolated from the colon at 10 weeks after cell administration, and the number of CD3$^+$CD4$^+$ cells was determined by flow cytometry. Data are indicated as the mean ± SEM of 7 mice in each group. *$P < .01$. (*E*) Phenotypic characterization of CD3$^+$CD4$^+$-gated T cells expressing CD25$^+$ or Foxp3$^+$ T_R cells in SP and LP of the mice in each group by FACS. Representatives of 7 separate samples in each group.



Figure 4. $CD4^+$ T cells penetrate epithelial barriers in colon. Splenic $CD4^+$ T cells from Ly5.1-background C57BL/6 mice were intrarectally administered to Ly5.2-background RAG-$2^{-/-}$ mice. Mice were killed at 3, 12, or 24 hours after administration. (*A*) Immunostaining of cytokeratin (*green*), CD3 (*red*), and 4'6-diamidino-2-phenylindole (*DAPI*) (*blue*) counterstaining. Representative of 4 separate samples in each group. Original magnification, ×100. (*B*) Electron microscopic analysis using intestinal samples at 3 hours after administration. Representative of 2 separate samples. Red square in the left panel was zoomed up to right panel. Original magnification, ×6000 (*left*) and ×10,000 (*right*).

istration and subsequently in the LP, MLN, and SP at 24 and 168 hours after administration (Figure 5). Similar emergence of intrarectally administered $CD4^+$ T cells first in the LP and later in the MLN and SP was confirmed in a similar experiment using immunosufficient C57/BL6 recipient mice (Figure 6). These results suggest that cells administered intrarectally were transferred from the LP to SP via afferent lymphatics to MLN but not directly via blood vessels exposed by ethanol treatment.

We further performed long-term experiment with GFP^+ donor/RAG-$2^{-/-}$ recipient system (Supplementary Figure 6*A*) in addition to $CD4^+$ donor/SCID recipient system (Figure 2) because it was possible that the existence of leaky $CD4^+$ T cells in SCID recipient mice affected our previous results. Ten weeks after the transfer, intrarectally, but not intravenously, administered GFP^+CD4^+ T cells expanded not only in colonic LP but also in the MLN, SP and BM, which led to develop colitis in RAG-$2^{-/-}$ recipient mice (Supplementary Figure 6*B–F*). We further checked cell surface markers of endogenous immune cells in addition to CD4 by fluorescence-activated cell sorter to clarify the accuracy of intrarectal administration of GFP^+CD4^+ cells. Indeed, $CD4^+$ cells contained both GFP^+ and GFP^- cells, CD3-gated $CD4^+$ T cells exclusively resided in GFP^+ subpopulation, but not in GFP^- subpopulation (Supplementary Figure 6*G*), suggesting that GFP^-CD4^+ cells are non-T cells, such as CD4-expressing macrophages and lymphoid tissue inducer cells. In contrast, $NK1.1^+$, $Gr1^+$, $CD11b^+$, and $CD11c^+$ cells preferentially resided in GFP^- cells (Supplementary Figure 6*H*), concluding that GFP^+ $CD3^+CD4^+$ T cells were all exogenous, but other immune compartments were all endogenous (Supplementary Figure 6*G*).

To further rule out the possibility that $CD4^+$ T cells egress through the colonic lymphoid organ in the intestine such as isolated lymphoid follicle, we performed intrarectally administration of $CD4^+$ T cells using $LT\alpha^{-/-}$ × RAG-$2^{-/-}$ mice, which lack such lymphoid organ. $LT\alpha^{-/-}$ × RAG-$2^{-/-}$ mice or RAG-$2^{-/-}$ mice were intrarectally administered with splenic $CD4^+$ T cells isolated from CAG-GFP Tg mice and were killed at 14 days after administration to assess the localization of $CD4^+$ T cells (Supplementary Figure 7*A*). The absolute numbers of $CD4^+$ T cells recovered from the LP, SP, and BM of



Figure 5. Intrarectally administered cells emerged in the LP and MLN before emerging in SP of recipient mice. (*A*) RAG-$2^{-/-}$ mice were administered $CD4^+$ T cells from CAG-GFP Tg mice intrarectally (1 × 10^7, *GFP-IR mice*, n = 4 at each time point) or intravenously (1 × 10^6, *GFP-IV mice*, n = 4 at each time point) and were killed at 6, 24, or 168 hours after administration. Representatives of 4 separate samples in each group. (*B*) Cells were isolated from LP, MLN, and SP at 6, 24, or 168 hours after administration, and the number of GFP^+ cells was determined by flow cytometery. Data are indicated as the mean ± standard error of mean of 4 mice in each group.

$LT\alpha^{-/-}$ × RAG-$2^{-/-}$ mice were equivalent to the paired absolute numbers from RAG-$2^{-/-}$ mice, suggesting that egress of $CD4^+$ T cells from LP is independent of gut-associated lymphoid tissue (GALT).

$CD4^+$ T Cells Egress From the Intestinal LP in CCR7- and $S1P_1$-Independent Manner

Given the evidence that administered $CD4^+$ T cells reside not only in the LP but also in MLN and SP of IR mice, we next attempted to investigate the molecular mechanism of egress of $CD4^+$ T cells from the intestinal LP. Recent reports have demonstrated that CCR7 plays a key role in the return of T cells to lymph node from peripheral tissues, such as lung and skin.[7,8] To assess whether this is the case with the egress of $CD4^+$ T cells from the LP, RAG-$2^{-/-}$ mice were intrarectally administered with splenic $CD4^+$ T cells isolated from wild-type (WT) (WT-IR) or CCR$7^{-/-}$ mice (CCR7-IR) and were killed at 14 days after administration (Figure 7*A*). Consistent with the above results, substantial numbers of $CD4^+$ T cells were recovered from the LP of WT-IR and CCR7-IR mice (Figure 7*B*). Notably, the numbers of $CD4^+$ T cells recovered from the LP, MLN, PB, SP, and BM of CCR7-IR mice were equivalent to paired numbers from WT-IR mice (Figure 7*B*), suggesting that egress from LP is mediated in a CCR7-independent manner. In addition to the above experiment, we performed another experiment to assess the possibility that egress of $CD4^+$ T cells from LP is mediated by S1P, which regulate the trafficking of lymphocytes in secondary lymphoid organs. RAG-$2^{-/-}$ mice were pretreated with phosphate-buffered saline or sphingosine-1-phosphate receptor agonist (FTY720) (1.0 mg/kg), which is the agonist of S1P receptor, daily starting 1 day before the transfer over a period of 2 weeks and were administered 3 × 10^6 $CD4^+$ T cells from WT C57BL/6. They were killed at 14 days after administration (Figure 7*C*). The number of $CD4^+$ T cells recovered from each organ of FTY720-treated mice was equivalent to paired number from control mice (Figure 7*D*), suggesting that $CD4^+$ T cells recovered from FTY720-treated mice could penetrate the gut wall and egress from the LP, and the egress of $CD4^+$ T cells from LP to afferent lymphatics is not mediated by $S1P_1$-dependent manner either.

Discussion

In the present study, by a series of intrarectal administration of living $CD4^+$ T cells into recipient mice, we demonstrated that $CD4^+$ T cells can not only penetrate from the intestinal lumen side to the LP but also egress from



Figure 6. Intrarectally administered cells emerged in the LP and MLN before emerging in SP of immunosufficient CB57/BL6 recipient mice. (*A*) C57/BL6 mice were administered $CD4^+$ T cells from CAG-GFP Tg mice intrarectally (1 × 10^7, *B6-IR mice*, n = 4 at each time point) or intravenously (1 × 10^6, *B6-IV mice*, n = 4 at each time point) and were killed at 6, 24, or 168 hours after administration. (*B*) Cells were isolated from LP, MLN, and spleen at 6, 24, or 168 hours after administration, and the absolute number of GFP^+ cells was determined by FACS. Data are indicated as the mean ± standard error of mean of 7 mice in each group.



Figure 7. Intrarectally administered cells egress from the LP in a CCR7- and a $S1P_1$- independent manners. (*A*) RAG-$2^{-/-}$ mice were intrarectally administered with 1×10^7 $CD4^+$ T cells from WT C57BL/6 mice (*WT-IR mice*, n = 5) or age-matched CCR$7^{-/-}$ mice (*CCR7-IR mice*, n = 5) and were killed at 14 days after administration. (*B*) Cells were isolated from LP, MLN, spleen, and BM at 14 days after administration, and the absolute number of $CD3^+CD4^+$ T cells recovered from each organ was determined by FACS. Data are indicated as the mean ± standard error of mean (SEM) of 7 mice in each group. *N. S.*, not significant. (*C*) RAG-$2^{-/-}$ mice were pretreated with phosphate-buffered saline or FTY720 (1.0 mg/kg) daily starting 1 day before the transfer over a period of 2 weeks and were administered 1×10^7 $CD4^+$ T cells from CAG-GFP Tg mice. Mice were killed at 14 days after administration. (*D*) Cells were isolated from LP, MLN, SP, and BM at 14 days after administration, and the number of $CD3^+CD4^+$ T cells was determined by flow cytometory. Data are indicated as the mean ± SEM of 7 mice in each group. *N. S.*, not significant.

the LP to the bloodstream in CCR7- and S1P-independent manners. Although the intestinal LP had been considered to be a "graveyard" of lymphocytes, which possesses a system that suppresses the egress of T cells from this tissue, we here showed experimentally that LP $CD4^+$ T cells are actively returned to systemic circulation.

Pathologically, it is well-known that immune cells, such as granulocytes and macrophages, can penetrate from the intestinal LP to lumen side and accumulate in intestinal crypts to form "crypt abscesses," which are often detected in active stage of UC.[12] In addition, microscopic examination of leukocytes in stool had long been recognized as an important diagnostic tool for patients with acute colitis.[18] Of particular note, Harris et al demonstrated that the stool leukocytes depend on a break in the integrity of intestinal epithelial cells in patients with typhoid fever, in which more than 90% of the white cells were predominantly mononuclear,[19] suggesting that lymphocytes are also able to transude to the intestinal lumen. Indeed, it is also well-known that T lymphocytes physiologically are able to reside in intraepithelial space as intraepithelial lymphocytes.[1,20] Furthermore, recent elegant works demonstrated that $CX3CR1^+$ DC beneath the epithelial cells in small intestine are able to open the tight junctions between adjacent epithelial cells and send dendrites out to sample luminal antigens directly.[11,21] These findings may support the possibility that immune cells actively shuttle between the lumen and the LP side. If so, the present system would be applicable to cell therapy in which protective cells, such as $CD4^+CD25^+Foxp3^+$ T_R cells, are administered intrarectally.

In this study, however, it was surprising that SCID mice intrarectally administered with splenic $CD4^+$ T cells including T_R cells developed colitis. In this regard, it was possible that naïve $CD4^+$ T, but not T_R cells, penetrate epithelial barriers and egress the LP, but this is not likely because we found both T_R and non-T_R cells in the LP and MLN and SP (Figure 3). Rather, it seems more likely that intrarectally administered T_R cells not only penetrate epithelial barriers but also egress the LP but that they cannot suppress the expansion of colitogenic $CD4^+$ T cells in the first initiation site, LP, of naïve $CD4^+$ T cells. In addition, it was also interesting

that the transepithelial migration of $CD4^+$ T cells in the intestine may be a universal phenomenon, as shown in mice of multiple immunological background, such as C.B.-17 SCID, C57BL/6 $RAG^{-/-}$, and C57BL/6 mice, in sharp contrast to the dendrites of $CX3CR1^+$ DC in small intestine are present in C57BL/6 but not in BALB/c mice.[22]

So far, it has been thought difficult to determine whether T cells in intestinal LP can exit the gut to afferent lymphatics. Although an in vivo experiment using a direct injection of cells into the footpad has successfully demonstrated that lymphocytes in peripheral skin tissue can egress in a CCR7-dependent manner,[8] in our hands, it was technically difficult to inject cells that can be distinguished by some molecular markers, such as GFP and Ly5.1, directly into the very thin intestinal wall of mice In addition, even if it were possible to insert a catheter into afferent lymphatics to directly drain cells by using large animals such as sheep, it still remains unclear whether those cells would definitely be derived from the intestinal LP because they could be a mixture of cells from sites including adipose tissues around the intestine and could be drained from the sites of primary LNs that are located closer to the intestine than the draining site.[23] Therefore, we administered cells by the intrarectal route to clarify 2 possible steps: lymphocyte penetration between epithelial barriers and the egress of lymphocytes from the intestinal LP.

This approach may also be open to criticism that cells administered by intrarectal enema would directly enter the small blood vessels, which is exposed to the intestinal lumen via ulcer caused by the ethanol treatment. However, this possibility was not likely because of the following findings: first, a small, but substantial, number of cells administered intrarectally were also found in the LP of recipient mice without ethanol treatment (Supplementary Figure 3); and, second, the first emergent site of cells in recipient mice after intrarectal administration was the LP, but not MLN or SP, in the time course experiment (Figures 5 and 6). Although our results using $CCR7^{-/-}$ mice could not demonstrate the CCR7 dependency of cell egress from the gut, this is not surprising because of the findings of 2 papers using $CCR7^{-/-}$ mice and/or CCR7-Tg mice in skin[8] and lung[7] systems that also demonstrated a CCR7-independent mechanism of cell egress in addition to CCR7-dependent one. In other words, the lack of evidence for CCR7 dependency of cell egress from the gut may explain why it has been so far believed that LP lymphocytes are not able to egress from the gut and thereby die there as if in a "graveyard."[1] Consistent with this, we also observed that intrarectally administered colitogenic $CD4^+CD44^{high}CD62L^-$ T_{EM} cells were subsequently detected in sites outside the intestine, such as MLN and SP (Figure 3).

In conclusion, we have here demonstrated 2 important findings: first, $CD4^+$ T cells are able to migrate from the lumen to the LP side through intraepithelial space; and, second, LP $CD4^+$ T cells are also able to egress from the LP systemically via the bloodstream. This new method may provide a tool for investigation of cell trafficking of intestinal mucosa and also a concept of cell therapy by enema administration for intestinal diseases including inflammatory bowel diseases. Supplementary Figure 8.

BASIC AND TRANSLATIONAL AT

Supplementary Material

Note: To access the supplementary material accompanying this article, visit the online version of *Gastroenterology* at www.gastrojournal.org, and at doi: 10.1053/j.gastro.2011.08.035.

References

1. Mowat AM. Anatomical basis of tolerance and immunity to intestinal antigens. Nat Rev Immunol 2000;3:331–341.
2. Mora JR, von Andrian U. T-cell homing specificity and plasticity: new concepts and future challenges. Trends Immunol 2006;27: 235–243.
3. Schwab SR, Cyster JG. Finding a way out: lymphocyte egress from lymphoid organs. Nat Immunol 2007;8:1295–1301.
4. Lefrancois L, Puddington L. Intestinal and pulmonary mucosal T cells: local heroes fight to maintain the status quo. Annu Rev Immunol 2006;24:681–704.
5. Yoffey JM. Variation in lymphocyte production. J Anat 1936;70: 507–514.
6. Gowans JL, Knight EJ. The route of re-circulation of lymphocytes in the rat. Proc R Soc Lond B Biol Sci 1964;159:257–282.
7. Bromley SK, Thomas SY, Luster AD. Chemokine receptor CCR7 guides T-cell exit from peripheral tissues and entry into afferent lymphatics. Nat Immunol 2005;6:895–901.
8. Debes GF, Arnold CN, Young AJ, et al. Chemokine receptor CCR7 required for T lymphocyte exit from peripheral tissues. Nat Immunol 2005;6:889–694.
9. Förster R, Schubel A, Breitfeld D, et al. CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell 1999;99:23–33.
10. Kawakami N, Sakane N, Nishizawa F, et al. Green fluorescent protein-transgenic mice: immune functions and their application to studies of lymphocyte development. Immunol Lett 1999;70: 165–171.
11. Niess JH, Brand S, Gu X, et al. CX3CR1-mediated dendritic cell access to the intestinal lumen and bacterial clearance. Science 2005;307:254–258.
12. Riddell RH. Pathology of idiopathic inflammatory bowel disease. Chapter 27 Sartor RB, Sandborn WJ, eds. Kirsner's inflammatory bowel disease. 6th ed Philadelphia, PA: Elsevier 2004:399–424.
13. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007;448:427–434.
14. Sartor RB. Microbial influences in inflammatory bowel diseases. Gastroenterology 2008;134:577–594.
15. O'Hara AM, Shanahan F. The gut flora as a forgotten organ. EMBO Rep 2006;7:688–693.
16. Surh CD, Boyman O, Purton JF, et al. Homeostasis of memory T cells. Immunol Rev 2006;211:154–163.
17. Rudolphi A, Bonhagen K, Reimann J. Polyclonal expansion of adoptively transferred $CD4^+$ $\alpha\beta$ T cells in the colonic lamina propria of scid mice with colitis. Eur J Immunol 1996;26:1156–1163.
18. Willmore JG, Sharman CH. On the differential diagnosis of the dysenteries. The diagnostic value of the cell-exudate in the stools of acute amoebic and bacillary dystery. Lancet 1918;192:200–216.
19. Harris JC, Dupont HL, Hornick RB. Fecal leukocytes in diarrheal illness. Ann Int Med 1972;76:697–703.

20. Cheroutre H. IELs: enforcing law and order in the court of the intestinal epithelium. Immunol Rev 2005;206:114–131.
21. Rescigno M, Urbano M, Valzasina B, et al. Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria. Nat Immunol 2001;2:361–367.
22. Vallon-Eberhard A, Landsman L, Yogev N, et al. Transepithelial pathogen uptake into the small intestinal lamina propria. J Immunol 2006;176:2465–2469.
23. Arstila T, Arstila TP, Calbo S, et al. Identical T-cell clones are located within the mouse gut epithelium and lamina propia and circulate in the thoracic duct lymph. J Exp Med 2000;191:823–834.

Received December 6, 2010. Accepted August 11, 2011.

Reprint requests

Address requests for reprints to: Mamoru Watanabe, MD, Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519. e-mail: mamoru.gast@tmd.ac.jp; fax: (81) 3-5803-0268.

Acknowledgments

The authors thank Peter Hawkes (Kansai Language College) for writing assistance and who was funded by grants-in-aid for Scientific Research, Scientific Research on Priority Areas, Exploratory Research.

Conflicts of interest

The authors disclose no conflicts.

Funding

Supported in part by grants-in-aid for Scientific Research, Scientific Research on Priority Areas, Exploratory Research, and Creative Scientific Research from the Japanese Ministry of Education, Culture, Sports, Science and Technology; the Japanese Ministry of Health, Labor and Welfare; the Japan Medical Association; and Foundation for Advancement of International Science.

BASIC AND TRANSLATIONAL AT

Supplementary Materials and Methods

Patients

Four patients with ulcerative colitis (UC) undergoing colorectomy at the Tokyo Medical and Dental University Hospital between 1999 and 2006 were enrolled in the study for immunohistochemical study (Supplementary Table 1).

Antibodies

Biotin-conjugated anti-mouse interleukin 7 Receptor alpha chain (A7R34) was obtained from eBioscinece (San Diego, CA). Fc gamma II/III receptor (CD16/CD32)-blocking monoclonal antibodies (mAb) (2.4G2), Phycoerythrin (PE)-, Peridinin chlorophyll protein (PerCP)-, and allophycocyanin (APC)-conjugated anti-mouse CD4 (RM4-5); fluorescein isothiocyanate (FITC)- and PerCP-conjugated anti-mouse CD3 (145-2C11); PE-conjugated anti-mouse CD44 (IM7); FITC-conjugated anti-mouse CD62L (MEL-14); PE-conjugated anti-mouse Ly5.1 (A20); FITC-conjugated anti-mouse B220 (RA3-6B2); FITC-conjugated anti-mouse NK1.1 (PK136); FITC-conjugated anti-mouse CD8a (53-6.7); and PE-conjugated streptavidin were obtained from BD PharMingen (San Diego, CA).

Purification of T-Cell Subsets

$CD4^+$ T cells were isolated from spleen and colon using the anti-CD4 (L3T4)- MACS system (Miltenyi Biotec, Auburn, CA) according to the manufacturer's instruction. To isolate normal lamina propria (LP) $CD4^+$ T cells, the entire length of the colon was opened longitudinally, washed with phosphate-buffered saline (PBS), and cut into small pieces. The dissected mucosa was incubated with Ca^{2+}, Mg^{2+}-free Hank's balanced salt solution containing 1 mmol/L dithiothreitol (Sigma-Aldrich, St. Louis, MO) for 45 minutes to remove mucus then treated with 3.0 mg/mL collagenase (Roshe Diagnosyics GmbH, Germany) and 0.01% DNase (Worthington Biomedical, Freehold, NJ) for 2 hours. The cells were pelleted 2 times through a 40% isotonic Percoll solution and then subjected to Ficoll-Hypaque density gradient centrifugation (40%/75%). Enriched $CD4^+$ T cells from the spleen and the colon (spleen: 94%–97% pure, as estimated by fluorescence-activated cell sorter [FACS] Calibur [Becton Dickinson, Sunnyvale, CA]) were used as donor cells.

Intrarectal Administration of $CD4^+$ T Cells

As a standard protocol of intestinal preparation, recipient mice were maintained without feeding for 1 hour and were given 1 mL of Niflec water (Ajinomoto Pharma Co, Tokyo, Japan) at the concentration of 69 g/L (standard concentration for human) 3 times at intervals of 1 hour by oral catheter. Thereafter, mice were pretreated with 1 mL of ethanol (50% concentration) or distilled water enema and subsequently with 5% pronase enema at 1 hour before cell administration. The method is illustrated in detail in Supplementary Figure 1. Experiment 1 (Figure 2*A* and *B*, Supplementary Figure 2): C.B-17 severe combined immunodeficient (SCID) recipient mice were administered with splenic $CD4^+$ T cells from normal BALB/c mice intrarectally (5×10^6) or intraperitoneally (5×10^5, as a control). Mice were monitored for clinical manifestations. The mice were killed at 10 weeks after administration and assessed for a clinical score that is the sum of 4 parameters as follows: hunching and wasting, 0 or 1; colon thickening, 0–3 (0, no colon thickening; 1, mild thickening; 2, moderate thickening; 3, extensive thickening); and stool consistency, 0–3 (0, normal beaded stool; soft stool; 2, diarrhea; and an additional point was added if gross blood was noted.[1–3] Experiment 2 (Figure 2*C–E*): Recombination-activating gene-2 $(RAG-2)^{-/-}$ mice were pretreated just like protocol of Supplementary Figure 1 (Mice with Niflec/Pronase) or without the pretreatments of Niflec and pronase (Mice w/o Niflec/Pronase) before cell administration. $RAG-2^{-/-}$ recipient mice in each group were administered with 5×10^6 $CD4^+$ T cells from CAG-GFP transgenic mice (n = 10 in each group). Experiment 3 (Supplementary Figure 3): SCID recipient mice were administered with splenic $CD4^+$ T cells from normal BALB/c mice intrarectally (5×10^6) with ethanol or PBS pretreatment. Mice were monitored for clinical manifestations. The mice were killed at 10 weeks after administration. Experiment 4 (Supplementary Figure 4): SCID mice were intrarectally administered with splenic whole $CD4^+$ T cells (5×10^6) or $CD4^+CD25^-$ T cells (5×10^6) from normal BALB/c mice intrarectally. Mice were monitored for clinical manifestations. Mice were killed at 7 weeks after administration and assessed for a clinical score as mentioned above. Experiment 5 (Supplementary Figure 5): Ly5.2-backgroud $RAG-2^{-/-}$ recipient mice were administered with $Ly5.1^+$ splenocytes intrarectally (1×10^8) or intraperitoneally (1×10^7). Mice were killed at 4 weeks after administration, and the absolute cell numbers of $Ly5.1^+$ donor-derived $CD3^+CD4^+$ T, $CD3^+CD8^+$ T, $CD3^+NK1.1^+$ NKT, $CD3^-NK1.1^+$ NK, and $B220^+$ B cells in spleen of recipient mice were assessed. Experiment 6 (Figure 3): SCID mice were intrarectally administered the same number (5×10^6) of colitogenic $CD4^+$ T cells obtained from colonic LP of colitic mice previously transferred with $CD4^+CD45RB^{high}$ T cells or $CD4^+$ T cells from SP of normal mice. The mice were killed at 10 weeks after administration. Experiment 7 (Figure 4): C57BL/6-background $RAG-2^{-/-}$ mice were administered with splenic $CD4^+$ T cells from CAG-GFP transgenic mice intrarectally (1×10^7) or intravenously (1×10^6, as a control). Mice were killed at 3, 12, or 24 hours after administration for immunohistochemical and electron microscopic analyses. Experiment 8 (Figure 5): C57BL/6-background $RAG-2^{-/-}$ mice were administered with splenic $CD4^+$ T cells from CAG-GFP Tg mice intrarectally (1×10^7) or intravenously (1×10^6, as a

control). Mice were killed at 6, 24, or 168 hours after administration for flow cytometric analysis. Experiment 9 (Figure 6): Immunosufficient C57BL/6 mice were administered with splenic $CD4^+$ T cells from CAG-GFP Tg mice intrarectally (B6-IR mice; 1×10^7 cells) or intravenously (B6-IV mice; 1×10^6 cells, as a control). Mice were killed at 6, 24, or 168 hours after administration for flow cytometric analysis. Experiment 10 (Supplementary Figure 6): C57BL/6-background RAG-$2^{-/-}$ mice were administered with splenic $CD4^+$ T cells from CAG-GFP Tg mice intrarectally (1×10^7) or intraperitoneally (1×10^6, as a control). Mice were killed at 10 weeks after administration for flow cytometric analysis. Experiment 11 (Supplementary Figure 7): RAG-$2^{-/-}$ or lymphotoxin α-deficient $\times$ RAG-$2^{-/-}$ mice were administered with splenic $CD4^+$ T cells from CAG-GFP Tg mice intrarectally (1×10^7). Mice were killed at 14 days after administration. Experiment 12 (Figure 7*A* and *B*): RAG-$2^{-/-}$ mice were intrarectally administered with 1×10^7 splenic $CD4^+$ T cells obtained from wild-type C57BL/6 or age-matched CCR$7^{-/-}$ mice and were killed at 14 days after administration. Experiment 13 (Figure 7*C* and *D*): RAG-$2^{-/-}$ mice were pretreated with PBS or FTY720 (1.0 mg/kg) daily starting 1 day before the transfer over a period of 2 weeks and were administered with 3×10^6 $CD4^+$ T cells from CAG-GFP Tg mice intrarectally (1×10^7). Mice were killed at 14 days after administration.

Immunohistochemistry

For mice studies, tissue samples were fixed in PBS containing 10% neutral-buffered formalin. Paraffin-embedded sections (5 mm) were stained with H&E. The sections were analyzed without prior knowledge of the type of T-cell reconstitution or recipient. The area most affected was graded by the number and severity of lesions. The mean degree of inflammation in the colon was calculated using a modification of a previously described scoring system.[1–3] Consecutive cryostat colon sections were used for immunohistochemistry with purified hamster mAb against CD3e (BD PharMingen, San Diego, CA) and rabbit polyclonal Ab against cytokeratine (DAKO, Glostrup, Denmark). Briefly, Optimal cutting temperature (O.C.T.) compound-embedded tissue samples were cut into serial sections 6 mm thick, placed on coated slides, and fixed with 4% paraformaldehyde phosphate buffer solution for 30 minutes. Slides were then incubated with the primary antibody at 4°C for overnight then stained with Alexa Fluor 594 goat anti-hamster immunoglobulin G (Invitrogen, San Diego, CA) for CD3e detection and with Alexa Fluor 488 donkey anti-rabbit immunoglobulin G for cytokeratine detection at room temperature for 60 minutes. All slides were counterstained with 4′, 6′-diamidino-2-phenylindole (DAPI; Vector Laboratories, Burlingame, CA) and observed under a confocal microscope (LSM510; Carl Zeiss, Jena, Germany). For human studies, sections (4 mm thick) of the colons and rectums were fixed in 10% buffered formalin and processed for routine pathologic examination. Two paraffin-embedded tissue blocks that included the most crypt abscesses were selected in each case and used for the study. The staining conditions are described in Supplementary Table 2.

Electron Microscopy

The colons of the mice were cut into 1-mm pieces and fixed in 2.5% glutaraldehyde and embedded in Epon. Ultrathin sections (95 nm thick) were cut on a Reichert Ultracut S (Leica Microsystems; Heidelberg GmbH, Mannheim, Germany) and collected on Maxtaform grids (Pyser-SGL Ltd, Kent, UK). The sections were double stained with uranyl acetate and lead citrate and examined with an H-7100 electron microscope (Hitachi High-Technologies Co, Tokyo, Japan).[4]

Flow Cytometry

To detect the surface expression of a variety of molecules, isolated spleen, mesenteric lymph node (MLN), or LP mononuclear cells were preincubated with an Fc gamma II/III receptor-blocking mAb (CD16/32; 2.4G2; BD PharMingen) for 15 minutes then incubated with specific FITC-, PE-, PerCP-, allophycocyanin- or biotin-labeled antibodies for 20 minutes on ice. Biotinylated antibodies were detected with PE-streptavidin. Standard 3- or 4-color flow cytometric analyses were obtained using the FACS Calibur with CellQuest software. Background fluorescence was assessed by staining with control-irrelevant isotype-matched mAbs.

Statistical Analysis

First, we examined the normality of each group If either of 2 groups was not normally distributed, we assessed the difference between the 2 groups, with the Mann–Whitney *U* test. If both groups were normally distributed, we assessed the variance of population to which each group belonged with the *F* test. With homoscedasticity of both populations, we assessed the difference between 2 groups, using the Student *t* test. Without homoscedasticity, we assessed the difference with the Welch *t* test. We used the program Statcell (OMS Ltd Tokorozawa, Saitama, Japan) for all statistical analysis. The results were expressed as the mean ± standard error of the mean. Differences were considered to be statistically significant when $P < .05$.

References

1. Makita S, Kanai T, Nemoto Y, et al. Intestinal lamina propria retaining $CD4^+CD25^+$ regulatory T cells is a suppressive site of intestinal inflammation. J Immunol 2007;178:4937–4946.
2. Totsuka T, Kanai T, Nemoto Y, et al. IL-7 is essential for the development and the persistence of chronic colitis. J Immunol 2007;178:4737–4748.
3. Nemoto Y, Kanai T, Makita S, et al. Bone marrow retaining colitogenic $CD4^+$ T cells may be a pathogenic reservoir for chronic colitis. Gastroenterology 2007;132:176–189.
4. Ito T, Kobayashi D, Uchida K, et al. *Helicobacter pylori* invades the gastric mucosa and translocates to the gastric lymph nodes. Lab Invest 2008;88:664–681.

Supplementary Table 1. Patients Enrolled in the Study

No.	Sex	Age, *y*	Pathologic diagnosis
UC1	Male	69	Ulcerative colitis, active phase of the colon and rectum
UC2	Male	68	Ulcerative colitis with toxic megacolon
UC3	Male	29	Adenocarcinoma of the descending colon. Ulcerative colitis
UC4	Male	53	Advanced rectal cancer. Ulcerative colitis

-Pre-medication

1, Give recipient mice 1ml of Niflec® (Ajinomoto Pharma Co., Tokyo), which is an oral bowel cleaner for human, at the concentration of 69g/L (standard concentration for human) three times at intervals of 1 hour, using oral catheter.
2, Stop any feed except water for recipient mice.



a. Gross appearance of the colon at day 2, after the pre-medication with Niflec®.

3, Six hours after the administration of Niflec®, insert the anal catheter into the colon of recipient mice to the depth of 3cm, and give 100μl 50% Ethanol through the catheter.
4, One hour after administration of Ethanol, 100μl 5% pronase (kaken Pharmaceutical Co., Ltd., Tokyo) was given to mice intrarectally as mentioned above.



b. Rectal catheter with 1ml syringe **c.** Mice fixation case

-Cell transfer

1, One hour after the pre-medication, insert the anal catheter into colon of recipient mice to the depth of 3cm (**d**), and give cells suspended to 200μl PBS. Reduce the defluvium using tweezers (**e**).
2, Shut the anal of recipient mice with the adhesive (**f**).



3, Six hours after the cell transfer, remove the adhesive from every mice.
4, Start feeding.

Supplementary Figure 1. Procedure of intrarectal administration of CD4$^+$ T cells into mice (*a*) Gross appearance of colon 6 after Niflec treatment. (*b*) Catheter with 1-mL syringe for pronase and ethanol treatment and intrarectal administration. (*c*) Mice fixation case. This device is made from a 50-mL Falcon tube. (*d–f*) Procedures for intrarectal cell administration.



Supplementary Figure 2. Intrarectal administration of splenic $CD4^+$ T cells into SCID mice induces chronic colitis. C.B-17 SCID recipient mice were administered with splenic $CD4^+$ T cells from normal BALB/c mice intrarectally (5×10^6, IR-SCID mice, n = 9) or intraperitoneally (5×10^5, IP-SCID mice, n = 9). (*A*) Gross appearance of the colon from IR- and IP-SCID mice at 10 weeks after cell administration. (*B*) Clinical scores were determined at 10 weeks after administration as described in the Materials and Methods section. Data are indicated as the mean ± standard error of mean (SEM) of 9 mice in each group. $^*P < .01$. (*C*) Histologic examination of the colon at 10 weeks after administration. Original magnification, ×40 (*upper panel*) and ×100 (*lower panel*). (*D*) Histologic scores were determined at 10 weeks after transfer as described in the Materials and Methods section. Data are indicated as mean ± SEM of 9 mice in each group. $^*P < .05$. (*E*) Phenotypic characterization of $CD3^+CD4^+$-gated T cells expressing CD44/CD62L in lamina propria (*LP*), mesenteric lymph node (MLN), peripheral blood (*PB*), and spleen (*SP*) of each group. Representatives of 9 separate samples in each group.



Supplementary Figure 3. Intrarectal administration of splenic CD4$^+$ T cells into SCID mice induces chronic colitis. (*A*) C.B-17 SCID recipient mice with or without pretreatment with 50% ethanol were intrarectally administered 5×10^6 CD4$^+$ T cells from normal BALB/c mice (n = 5 in each group). (*B*) LP, MLN, and spleen CD3$^+$CD4$^+$ T cells were isolated from the colon at 10 weeks after T-cell administration, and the number of CD3$^+$CD4$^+$ cells was determined by flow cytometry. Data are indicated as the mean ± standard error of mean of 9 mice in each group. *N. S.*, not significant.



Supplementary Figure 4. SCID mice intrarectally administered with whole $CD4^+$ or $CD4^+CD25^-$ T cells similarly develop colitis. (*A*) C.B-17 SCID recipient mice were intrarectally administered 5×10^6 whole $CD4^+$ T cells or $CD4^+CD25^-$ T cells from normal BALB/c mice. (n = 5 in each group) (*B*) LP, MLN, and spleen $CD3^+CD4^+$ T cells were isolated from the colon at 7 weeks after T-cell administration, and the number of $CD3^+CD4^+$ cells was determined by flow cytometry. Data are indicated as the mean ± SEM of nine mice in each group. *N. S.*, not significant.



Supplementary Figure 5. Various Ly5.1$^+$ lymphocytes can be detected in SP of RAG-2$^{-/-}$ mice intrarectally administered with Ly5.1$^+$ splenocytes. (*A*) One $\times$ 10^8 splenocytes from Ly5.1$^+$ C57BL/6 mice were intrarectally administered to Ly5.2$^+$RAG-2 recipients (Ly5.1$^+$ IR). As a positive control, 1 $\times$ 10^7 splenocytes from Ly5.1$^+$ C57BL/6 mice were intravenously administered to Ly5.2$^+$RAG-2 recipients (Ly5.1$^+$ IR) (n = 5 in each group). (*B*) Splenocytes were isolated from mice in each group at 4 weeks after T-cell administration, and the number of Ly5.1$^+$CD3$^+$CD4$^+$ (CD4$^+$ T), Ly5.1$^+$CD3$^+$CD8$^+$ (CD8$^+$ T), Ly5.1$^+$CD3$^+$NK1.1$^+$ (NKT), Ly5.1$^+$CD3$^-$NK1.1$^+$ (NK), B220$^+$ (B) cells were determined by flow cytometry. Data are indicated as the mean $\pm$ standard error of mean of 9 mice in each group. *$P < .01$. *N. S.*, not significant.



Supplementary Figure 6. Intrarectal administration of splenic GFP$^+$CD4$^+$ T cells into RAG-2$^{-/-}$ mice induces chronic colitis. (*A*) RAG-2$^{-/-}$ mice were administered with CD4$^+$ T cells from CAG-GFP transgenic mice intrarectally (5 × 10^6, IR-RAG, mice, n = 3) or intraperitoneally (5 × 10^5, IP-RAG mice, n = 3). (*B*) Gross appearance of the colon from IR- and IP-RAG mice at 10 weeks after cell administration. (*C*) Clinical scores were determined at 10 weeks after administration as described in Supplementary Materials and Methods section. Data are indicated as the mean ± standard error of mean (SEM) of 3 mice in each group. *P = .0026. (*D*) Histologic examination of the colon at 10 weeks after administration. Original magnification, ×20 (*upper panel*) and ×200 (*lower panel*). (*E*) Histologic scores were determined at 10 weeks after transfer as described in Supplementary Materials and Methods section. Data are indicated as mean ± SEM of 3 mice in each group. *P = .0018. (*F*) Lamina propria (*LP*), mesenteric lymph node (*MLN*), spleen (*SP*), and bone marrow (*BM*) cells were isolated from the colon at 10 weeks after T-cell administration, and the absolute number of GFP$^+$CD3$^+$CD4$^+$ cells was determined by FACS. Data are indicated as the mean ± SEM of 9 mice in each group. *P = .0015. N. S. means not significant difference. (*G*) Expression of GFP in whole CD4$^+$ cells (*upper panel*) and CD3-gated CD4$^+$ cells (*lower panel*) on GFP$^+$ cells of SP from RAG-2$^{-/-}$ mice in each group were assessed by FACS. *Dot plot* is representative one of each group. Representatives of 9 separate samples in each group. (*H*) Endogenous cell surface markers on cells of spleen from each group were assessed by FACS. *Dot plot* analysis of FACS is representative one of each group. Representatives of 3 separate samples in each group.





Supplementary Figure 7. Egress of $CD4^+$ T cells from LP is independent of Gut-associated lymphoid tissue (GALT). (*A*) Lymphotoxin α-deficient ($LT\alpha^{-/-}$) × $RAG\text{-}2^{-/-}$ mice or $RAG\text{-}2^{-/-}$ mice were administered $CD4^+$ T cells from CAG-GFP Tg mice intrarectally (1×10^7) and were killed at 14 days after administration. (*B*) Cells were isolated from LP, MLN, SP and BM at 14 days after administration, and the number of GFP^+CD4^+ T cells was determined by flow cytometery. Data are indicated as the mean ± standard error of mean of 5 mice in each group. $^*P < .05$. *N. S.*, not significant.



Supplementary Figure 8. Model of $CD4^+$ T-cell penetration across intestinal barriers and its egress from LP to systemic circulation. $CD4^+$ T cells not only penetrate from the intestinal luminal side to the LP but also egress from the LP to the bloodstream in a CCR7-independent manner.

Supplementary Table 2. Antibodies Used in the Study

Antibodies	Manufactures	Antigen retrieval method	Buffer pH for the retrieval	Working dilution	Incubation time and temperature	Second antibody
CD20	Dako, Glostrup, Denmark	MW, 40 min	9.0	1:1	1 h, RT	ABC
CD3	Novocastra, Newcastle, UK	MW, 40 min	9.0	1:20	1 h, RT	ABC
CD4	Novovastra, Newcastle, UK	AC, 20 min	9.0	1:50	24 h, 4°C	ABC
CD8	Dako, Glostrup, Denmark	AC, 20 min	6.0	1:100	24 h, 4°C	ABC
CD56	Novovastra, Newcastle, UK	AC, 20 min	6.0	1:500	24 h, 4°C	ABC
MPO	Dako, Glostrup, Denmark	MW, 40 min	9.0	1:4000	1 h, RT	EnVision

ABC, ABC immunoperoxidase kit (Vector Laboratories, Burlingame, CA); AC, autoclave; EnVision, EnVision+ System (Dako); RT, room temperature; MPO, myeloperoxidase; MW, microwave.

Regulatory T Cells Suppress Development of Colitis, Blocking Differentiation of T-Helper 17 Into Alternative T-Helper 1 Cells

TOMOHISA SUJINO,* TAKANORI KANAI,* YUICHI ONO,* YOHEI MIKAMI,* ATSUSHI HAYASHI,* TOMOMITSU DOI,* KATSUYOSHI MATSUOKA,* TADAKAZU HISAMATSU,* HIROMASA TAKAISHI,* HARUHIKO OGATA,* AKIHIKO YOSHIMURA,‡ DAN R. LITTMAN,§ and TOSHIFUMI HIBI*

*Division of Gastroenterology and Hepatology, Department of Internal Medicine and ‡Department of Microbiology and Immunology, Keio University School of Medicine, Tokyo, Japan; §Molecular Pathogenesis Program, The Kimmel Center for Biology and Medicine of the Skirball Institute, New York University School of Medicine, New York, New York

See editorial on page 801.

BACKGROUND & AIMS: Although T-helper (Th) 17 and Th1 cells are involved in pathogenesis of intestinal inflammation, their developmental pathways and sufficiency to promote disease are not known; nor are the roles of $CD4^+CD25^+$ regulatory T (T_R) cells in their development. **METHODS:** We performed adoptive transfer experiments to investigate the induction and suppression of colitis using naïve $CD4^+CD45RB^{high}$ T cells and/or $CD4^+CD25^+$ T_R cells that were obtained from retinoid-related orphan receptor gamma t (RORγt) *gfp*/+ or Ly5.1/Ly5.2 congenic mice. **RESULTS:** We observed 3 types of colitogenic $CD4^+$ Th1 cells (interleukin [IL]-$17A^-$interferon [IFN]-γ^+): $ROR\gamma t^-$ classical Th1 cells that differentiated directly from naïve T cells; $ROR\gamma t^+$ Th1-like cells; and $ROR\gamma t^-$ alternative Th1 cells that were terminally differentiated from $ROR\gamma t^+$ cells via Th17 (IL-$17A^+$IFN-γ^-), Th17/Th1 (IL-$17A^+$IFN-γ^+), or Th1-like (IL-$17A^-$IFN-γ^+) cells. In this pathway, $CD4^+CD25^+$ T_R cells suppress the development of not only classical Th1 cells, but also alternative Th1 cells at the transition of Th17/Th1 into alternative Th1 cells, resulting in accumulation of Th17 and Th17/Th1 cells in mice in which the development of colitis was suppressed. Furthermore, T_R cells regulated the established balance of Th17 and Th1 cells under colitic conditions to yield a high ratio of Th17 and Th17/Th1 cells to Th1 cells in noncolitic conditions. **CONCLUSIONS: Th17 and Th17/Th1 cells become colitogenic alternative Th1 cells via Th17, Th17/Th1, and Th1-like cells, independently of classical Th1 cells. T_R cells suppress this pathway, resulting in accumulation of Th17 and Th17/Th1 cells.**

Keywords: Inflammatory Bowel Disease; Mouse Model; T-Cell Development; Immune Response.

T-helper-17 (Th17) cells are characterized by production of Th17 cytokines, such as interleukin (IL)-17A[1]; expression of retinoid-related orphan receptor gamma t (ROR γt)[2,3]; and induction of massive tissue inflammation in various immune diseases in a manner similar to T-bet transcription factor–governed IFN-γ–producing Th1 cells.[1,2,4] Interestingly, naturally occurring Th17 cells reside preferentially in the intestine in healthy mice,[3,5] and may control a variety of bacterial and fungal infections at mucosal sites.

Questions about the distinction and correlation between the roles of colitogenic Th17 and Th1 cells, and their pathogenicity in inflammatory bowel disease (IBD) remain largely unanswered. For instance, it has been reported that recombination activating gene (RAG)-$2^{-/-}$ mice transferred with naïve T cells obtained from either T-$bet^{-/-}$[6] or $ROR\gamma^{-/-}$ mice[7] do not develop colitis. Furthermore, in animal IBD models,[8,9] a distinct subset of IL-$17A^+$IFN-γ^+ Th17/Th1 cells may participate in the pathogenesis of each disease. This is complicated further by a recent report showing that colitogenic "Th1-like" cells emerge directly from Th17 cells at a late stage of the colitis developmental process.[10]

Based on such complex backgrounds, we aimed to clarify not only the developmental pathway of Th17, Th17/Th1, and Th1 cells in the pathogenesis of colitis, but also the role of $CD4^+CD25^+Foxp3^+$ regulatory T (T_R) cells in their developmental pathway using an in vivo adoptive T-cell transfer model, in which RAG-1, $2^{-/-}$ mice transferred with $CD4^+CD45RB^{high}$ T cells develop chronic colitis 4–6 weeks after transfer.[11] This model is advantageous, as the transferred cells can be traced during development or suppression of colitis over time, without having to continually supply naïve $CD4^+$ T cells.[12] This model is controlled by T_R cells possibly by suppressing the generation and maintenance of colitogenic Th1 and Th17 cells.[7,13,14]

Materials and Methods

Mice

C57BL/6 (Ly5.1), C57BL/6 (Ly5.2), and C57BL/6-background RAG-$2^{-/-}$ (Ly5.2) mice were obtained from Taconic Laboratory (Hudson, NY) and Central Laboratories for Experimental Animals (Kawasaki, Japan). Mice with a green fluores-

Abbreviations used in this paper: CTLA, cytotoxic T lymphocyte–associated antigen; GFP, green fluorescent protein; Gr, Group; IBD, inflammatory bowel disease; IFN, interferon; LP, lamina propria; mRNA, messenger RNA; RAG, recombination activating gene; RORγt, retinoid-related orphan receptor gamma t; TGF, transforming growth factor; Th, T helper; TNF, tumor necrosis factor; T_R, regulatory T.

© 2011 by the AGA Institute
0016-5085/$36.00
doi:10.1053/j.gastro.2011.05.052